RxDoctor Payments Data

John Baugh, MD

Cardiovascular Disease · Columbia, SCNPI 1942208707

Payments from drug & device makers

$9,304in general payments, 2019–2025

Across 547 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Amgen$907
  • E.r. Squibb & Sons, L.L.C.$766
  • Boston Scientific$717
  • Johnson & Johnson$680
  • Pfizer$657
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$9,304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,304 in reported general payments places this provider in the 70th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$323,203
Medicare patients
1,942
Services billed
5,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$161,886
XareltoRivaroxaban145$137,684
JardianceEmpagliflozin46$53,983
EntrestoSacubitril/Valsartan36$41,728
Repatha SureclickEvolocumab25$28,482
FarxigaDapagliflozin Propanediol30$26,785
BrilintaTicagrelor25$14,490
NexlizetBempedoic Acid/Ezetimibe11$10,758
Rosuvastatin Calcium364$7,550
Metoprolol Succinate399$6,918
Atorvastatin Calcium381$4,018
Valsartan116$3,742
SotalolSotalol Hcl112$3,440
Ezetimibe70$2,785
Prasugrel Hcl33$2,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$657$161,886149 claims
Johnson & JohnsonXarelto$680$137,684145 claims
Boehringer IngelheimJardiance$188$53,98346 claims
NovartisEntresto$1,557$41,72836 claims
AstraZenecaFarxiga, Brilinta$490$41,27555 claims
Esperion Therapeutics, Inc.Nexlizet$482$10,75811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →